How could the FDA's positive vote on Galleri affect Quest Diagnostics?
Quest Diagnostics may scale testing volume following Galleri's FDA approval The FDA's positive vote on the safety and effectiveness of GRAIL's Galleri test paves the way for marketing approval, significantly increasing the test's market viability. Because GRAIL integrates its diagnostic tests into Quest Diagnostics' collection and testing network, increased market demand for Galleri would translate into higher testing volume for Quest. However, the ultimate scale of this effect depends on whether medical insurers and bodies are willing to adopt the test, which currently has a list price of $949, and whether they accept the cost-benefit calculations regarding false positives.
- Effect
- Mild positive
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- Gone quiet
How it reaches Quest Diagnostics
-
The FDA's Medical Devices Advisory Committee's Molecular and Clinical Genetics Devices Panel voted in favor of Galleri's safety, benefit, and effectiveness. This vote paves the way for FDA marketing approval for the test.
The full event1independent outlet -
GRAIL integrates its diagnostic tests into Quest Diagnostics' collection and testing network, leveraging Quest's infrastructure for service delivery. Increased market acceptance of Galleri due to the FDA vote could drive higher demand for the test, increasing the volume processed through Quest's system.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
medical research company
Everything about Quest Diagnostics
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The FDA's Medical Devices Advisory Committee voted in favor of Galleri's safety, benefit, and effectiveness.fool.com
- The test currently has a list price of $949.fool.com
- The key decision regarding adoption involves weighing benefits against factors such as its cost and the number of false positives it produces.fool.com
Why it matters
For Quest Diagnostics, which relies on large-scale diagnostic partnerships, this FDA approval validates a major new service line. The ability to integrate a high-profile, multi-cancer early detection test like Galleri into its existing collection and testing network represents a significant opportunity for increased operational throughput and revenue.
The broader market for multi-cancer early detection tests is highly speculative, as noted by the focus on cost-benefit considerations. While the FDA approval is a major regulatory hurdle cleared, the actual financial impact on Quest will hinge on whether major medical insurers and bodies are willing to adopt the test and cover its cost.
What we don't know yet
- Will major medical insurers adopt the Galleri test despite its current list price of $949?
- What specific clinical data will GRAIL present to insurers to justify the test's cost-benefit ratio?
What would change this answer
— Other considerations
Beyond this explainer
Explore connected ideas
Each opens in Related concepts: what the web connects to it, with Brind's news on it.
The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.
Who else could feel it
Other possible ripples from the same event.
- NateraLikelyGrail's regulatory success increases competitive pressure on Natera
- IlluminaLikelyIllumina's financial stake may benefit from Galleri's FDA approval
- TricarePossibleGalleri test FDA approval may expand Tricare's covered services
- MedicarePossibleMedicare must now evaluate the Galleri test for reimbursement following FDA approval.
Reporting
- fool.comOct 11
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.